Literature DB >> 19375789

Current and emerging trends in Lynch syndrome identification in women with endometrial cancer.

Kimberly E Resnick1, Heather Hampel, Richard Fishel, David E Cohn.   

Abstract

OBJECTIVE: Lynch syndrome is a heritable, cancer susceptibility syndrome. This study aims to review current and emerging trends in the identification of Lynch syndrome in the endometrial cancer patient population.
METHODS: We performed a comprehensive review of past and present screening algorithms for Lynch syndrome, including a review of the utility of both the Amsterdam criteria and Bethesda guidelines. Because non-colon cancers have historically not been the focus of Lynch syndrome research, current literature is ripe with questions regarding screening among this patient population. Low BMI, age less than 50, positive family history and pathologic features have all been identified as risk factors in endometrial cancer patients who might benefit from Lynch screening. Additionally, based on experience at our own institution we offer a feasible screening algorithm for these patients.
RESULTS: A comprehensive review of the data demonstrated that immunohistochemistry is becoming an efficient, inexpensive way to screen tumors at risk for mismatch repair deficiency. The sensitivity and specificity of immunohistochemistry for predicting Lynch syndrome approaches 100%. Ideally, prospective screening of all endometrial cancer patients with IHC is a feasible, cost-efficient way to detect Lynch in this patient population given the limitations of using personal/family history of malignancy as well as pathologic risk factors.
CONCLUSION: It is imperative that clinicians be mindful of the risk of Lynch syndrome in women with endometrial cancer. Given the opportunity for colon cancer screening and prevention strategies to be initiated, the identification of probands with endometrial cancer as a result of Lynch syndrome will lead to a reduction in morbidity and mortality for these patients and their families.

Entities:  

Mesh:

Year:  2009        PMID: 19375789      PMCID: PMC2841434          DOI: 10.1016/j.ygyno.2009.03.003

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  41 in total

1.  Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1.

Authors:  S Syngal; E A Fox; C Eng; R D Kolodner; J E Garber
Journal:  J Med Genet       Date:  2000-09       Impact factor: 6.318

2.  Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.

Authors:  Paul J Goodfellow; Barbara M Buttin; Thomas J Herzog; Janet S Rader; Randall K Gibb; Elizabeth Swisher; Katherine Look; Ken C Walls; Ming-Yu Fan; David G Mutch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

3.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

4.  RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.

Authors:  David G Mutch; Matthew A Powell; Mary Ann Mallon; Paul J Goodfellow
Journal:  Am J Obstet Gynecol       Date:  2004-04       Impact factor: 8.661

5.  The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer.

Authors:  H F Vasen; P Watson; J P Mecklin; J R Jass; J S Green; T Nomizu; H Müller; H T Lynch
Journal:  Anticancer Res       Date:  1994 Jul-Aug       Impact factor: 2.480

6.  Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer.

Authors:  Jinru Shia; Nathan A Ellis; Philip B Paty; Garrett M Nash; Jing Qin; Kenneth Offit; Xin-Min Zhang; Arnold J Markowitz; Khedoudja Nafa; Jose G Guillem; W Douglas Wong; William L Gerald; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2003-11       Impact factor: 6.394

7.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

Authors:  J G Herman; A Umar; K Polyak; J R Graff; N Ahuja; J P Issa; S Markowitz; J K Willson; S R Hamilton; K W Kinzler; M F Kane; R D Kolodner; B Vogelstein; T A Kunkel; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

8.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

9.  Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.

Authors:  Barbara M Buttin; Matthew A Powell; David G Mutch; Sheri A Babb; Phyllis C Huettner; Tina Bocker Edmonston; Thomas J Herzog; Janet S Rader; Randall K Gibb; Alison J Whelan; Paul J Goodfellow
Journal:  Am J Hum Genet       Date:  2004-04-19       Impact factor: 11.025

10.  Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome.

Authors:  Shannon N Westin; Robin A Lacour; Diana L Urbauer; Rajyalakshmi Luthra; Diane C Bodurka; Karen H Lu; Russell R Broaddus
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

View more
  30 in total

1.  Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.

Authors:  Terri Febbraro; Katina Robison; Jennifer Scalia Wilbur; Jessica Laprise; Amy Bregar; Vrishali Lopes; Robert Legare; Ashley Stuckey
Journal:  Gynecol Oncol       Date:  2015-04-28       Impact factor: 5.482

2.  Current Lynch syndrome tumor screening practices: a survey of genetic counselors.

Authors:  Stephanie A Cohen
Journal:  J Genet Couns       Date:  2013-05-15       Impact factor: 2.537

Review 3.  Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Annessa Kernberg; Russell R Broaddus
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

4.  Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Diana L Urbauer; Shannon N Westin; Pamela T Soliman; Karen H Lu; Rajyalakshmi Luthra; Russell R Broaddus
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 6.  Management of genetic syndromes predisposing to gynecologic cancers.

Authors:  Susan Miesfeldt; Amanda Lamb; Christine Duarte
Journal:  Curr Treat Options Oncol       Date:  2013-03

7.  Development of an integrated support system for hereditary cancer and its impact on gynecologic services.

Authors:  Mina Morii-Kashima; Hiroshi Tsubamoto; Chika Sato; Mariko Ushioda; Naohiro Tomita; Yasuo Miyoshi; Tomoko Hashimoto-Tamaoki; Kazuo Tamura; Hideaki Sawai; Hiroaki Shibahara
Journal:  Int J Clin Oncol       Date:  2013-12-19       Impact factor: 3.402

8.  Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer.

Authors:  Ji-Hyun Lee; Deborah Cragun; Zachary Thompson; Domenico Coppola; Santo V Nicosia; Mohammad Akbari; Shiyu Zhang; John McLaughlin; Steven Narod; Joellen Schildkraut; Thomas A Sellers; Tuya Pal
Journal:  Genet Test Mol Biomarkers       Date:  2014-03-04

Review 9.  Genetics of endometrial cancer.

Authors:  Ayelet Shai; Yakir Segev; Steven A Narod
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

10.  A case of endometrial cancer in the context of a BRCA2 mutation and double heterozygosity for Lynch syndrome.

Authors:  Ping Gong; Sarah Charles; Norman Rosenblum; Zoe Wang; Agnieszka K Witkiewicz
Journal:  Gynecol Oncol Case Rep       Date:  2012-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.